Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kringle advances HGF therapy for renal failure

This article was originally published in Scrip

Executive Summary

The Japanese bioventure Kringle Pharma has filed a US IND to begin clinical trials with a recombinant hepatocyte growth factor for the treatment of acute renal failure (ARF). The disorder, which is associated with a range of conditions including shock, has a mortality rate of around 50% and is now treated only symptomatically, Kringle notes. HGF is under-expressed in the condition, which affects around 700,000 people in the US, and studies suggest that administration of additional quantities aids the regeneration of renal function, the Osaka-based firm said. It has already partnered with the Swedish company Tripep to develop HGF for chronic leg wounds.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts